{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T11:59:10Z","timestamp":1794916750118,"version":"4.9.1"},"reference-count":135,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,5,25]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy characterized by intravascular hemolysis, thrombocytopenia, and acute kidney failure. HUS is usually categorized as typical, caused by Shiga toxin\u2013producing Escherichia coli (STEC) infection, as atypical HUS (aHUS), usually caused by uncontrolled complement activation, or as secondary HUS with a coexisting disease. In recent years, a general understanding of the pathogenetic mechanisms driving HUS has increased. Typical HUS (ie, STEC-HUS) follows a gastrointestinal infection with STEC, whereas aHUS is associated primarily with mutations or autoantibodies leading to dysregulated complement activation. Among the 30% to 50% of patients with HUS who have no detectable complement defect, some have either impaired diacylglycerol kinase \u03b5 (DGK\u03b5) activity, cobalamin C deficiency, or plasminogen deficiency. Some have secondary HUS with a coexisting disease or trigger such as autoimmunity, transplantation, cancer, infection, certain cytotoxic drugs, or pregnancy. The common pathogenetic features in STEC-HUS, aHUS, and secondary HUS are simultaneous damage to endothelial cells, intravascular hemolysis, and activation of platelets leading to a procoagulative state, formation of microthrombi, and tissue damage. In this review, the differences and similarities in the pathogenesis of STEC-HUS, aHUS, and secondary HUS are discussed. Common for the pathogenesis seems to be the vicious cycle of complement activation, endothelial cell damage, platelet activation, and thrombosis. This process can be stopped by therapeutic complement inhibition in most patients with aHUS, but usually not those with a DGK\u03b5 mutation, and some patients with STEC-HUS or secondary HUS. Therefore, understanding the pathogenesis of the different forms of HUS may prove helpful in clinical practice.<\/jats:p>","DOI":"10.1182\/blood-2016-11-709865","type":"journal-article","created":{"date-parts":[[2017,4,18]],"date-time":"2017-04-18T01:00:22Z","timestamp":1492477222000},"page":"2847-2856","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":263,"title":["HUS and atypical HUS"],"prefix":"10.1182","volume":"129","author":[{"given":"T. Sakari","family":"Jokiranta","sequence":"first","affiliation":[{"name":"Research Programs Unit, Immunobiology, University of Helsinki, Helsinki University Central Hospital, and United Medix Laboratories, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2019111903323609200_B1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00281-014-0416-x","article-title":"Hemolytic uremic syndrome","volume":"36","author":"Mele","year":"2014","journal-title":"Semin Immunopathol"},{"issue":"1","key":"2019111903323609200_B2","first-page":"114","article-title":"HELLP syndrome and its relation with the antiphospholipid syndrome","volume":"12","author":"Tufano","year":"2014","journal-title":"Blood Transfus"},{"issue":"6","key":"2019111903323609200_B3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3343\/alm.2016.36.6.505","article-title":"Current pathological and laboratory considerations in the diagnosis of disseminated intravascular coagulation","volume":"36","author":"Toh","year":"2016","journal-title":"Ann Lab Med"},{"issue":"4","key":"2019111903323609200_B4","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jash.2015.12.007","article-title":"The endothelium as the common denominator in malignant hypertension and thrombotic microangiopathy","volume":"10","author":"Mathew","year":"2016","journal-title":"J Am Soc Hypertens"},{"issue":"1","key":"2019111903323609200_B5","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s11926-014-0482-z","article-title":"Catastrophic APS in the context of other thrombotic microangiopathies","volume":"17","author":"Rodr\u00edguez-Pint\u00f3","year":"2015","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"2019111903323609200_B6","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrneph.2016.124","article-title":"Scleroderma renal crisis and renal involvement in systemic sclerosis","volume":"12","author":"Woodworth","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"2019111903323609200_B7","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1523-1755.1998.00824.x","article-title":"Genetic studies into inherited and sporadic hemolytic uremic syndrome","volume":"53","author":"Warwicker","year":"1998","journal-title":"Kidney Int"},{"issue":"1","key":"2019111903323609200_B8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.molimm.2015.03.246","article-title":"Atypical aHUS: State of the art","volume":"67","author":"Nester","year":"2015","journal-title":"Mol Immunol"},{"issue":"6","key":"2019111903323609200_B9","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.imbio.2015.05.015","article-title":"Complement genetics and susceptibility to inflammatory disease. Lessons from genotype-phenotype correlations","volume":"221","author":"de C\u00f3rdoba","year":"2016","journal-title":"Immunobiology"},{"issue":"5","key":"2019111903323609200_B10","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet"},{"issue":"1","key":"2019111903323609200_B11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.2013050453","article-title":"Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome","volume":"25","author":"Bu","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2019111903323609200_B12","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10157-010-0375-z","article-title":"A case of atypical hemolytic uremic syndrome due to anti-factor H antibody in a patient presenting with a factor XII deficiency identified two novel mutations","volume":"15","author":"Matsukuma","year":"2011","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"2019111903323609200_B13","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic-uremic syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111903323609200_B14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00281-011-0282-8","article-title":"Thrombomodulin and its role in inflammation","volume":"34","author":"Conway","year":"2012","journal-title":"Semin Immunopathol"},{"issue":"1","key":"2019111903323609200_B15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr Nephrol"},{"issue":"6066","key":"2019111903323609200_B16","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1126\/science.1215930","article-title":"Manganese blocks intracellular trafficking of Shiga toxin and protects against Shiga toxicosis","volume":"335","author":"Mukhopadhyay","year":"2012","journal-title":"Science"},{"issue":"6","key":"2019111903323609200_B17","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.thromres.2013.03.006","article-title":"Shiga toxin downregulates tissue factor pathway inhibitor, modulating an increase in the expression of functional tissue factor on endothelium","volume":"131","author":"Grabowski","year":"2013","journal-title":"Thromb Res"},{"issue":"4","key":"2019111903323609200_B18","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1055\/s-0034-1375295","article-title":"Role of complement in enterohemorrhagic Escherichia coli-Induced hemolytic uremic syndrome","volume":"40","author":"Orth-H\u00f6ller","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"2019111903323609200_B19","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.4049\/jimmunol.1402470","article-title":"Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome","volume":"194","author":"Arvidsson","year":"2015","journal-title":"J Immunol"},{"issue":"2","key":"2019111903323609200_B20","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1055\/s-2006-939769","article-title":"Platelet activation in hemolytic uremic syndrome","volume":"32","author":"Karpman","year":"2006","journal-title":"Semin Thromb Hemost"},{"issue":"10","key":"2019111903323609200_B21","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1093\/ndt\/gfs394","article-title":"Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry","volume":"27","author":"Kielstein","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"2019111903323609200_B22","doi-asserted-by":"crossref","first-page":"e70431","DOI":"10.1371\/journal.pone.0070431","article-title":"Action of shiga toxin type-2 and subtilase cytotoxin on human microvascular endothelial cells","volume":"8","author":"Amaral","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"2019111903323609200_B23","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1093\/ndt\/gft198","article-title":"The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome","volume":"28","author":"Szil\u00e1gyi","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2019111903323609200_B24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00467-010-1690-z","article-title":"Pandemic H1N1 influenza A infection and (atypical) HUS--more than just another trigger?","volume":"26","author":"Allen","year":"2011","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"2019111903323609200_B25","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.transproceed.2012.07.039","article-title":"De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment, and long-term patient and graft survival","volume":"44","author":"Caires","year":"2012","journal-title":"Transplant Proc"},{"issue":"7","key":"2019111903323609200_B26","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/j.1600-6143.2010.03156.x","article-title":"Thrombotic microangiopathy after kidney transplantation","volume":"10","author":"Noris","year":"2010","journal-title":"Am J Transplant"},{"issue":"2","key":"2019111903323609200_B27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/1076029615599439","article-title":"Eculizumab in transplant-associated thrombotic microangiopathy","volume":"23","author":"Dhakal","year":"2015","journal-title":"Clin Appl Thromb Hemost"},{"issue":"9","key":"2019111903323609200_B28","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/bmt.2016.87","article-title":"Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy","volume":"51","author":"Vasu","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2019111903323609200_B29","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar4142","article-title":"The spectrum of renal thrombotic microangiopathy in lupus nephritis","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"2019111903323609200_B30","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0272-6386(12)80543-9","article-title":"Renal thrombotic microangiopathy in patients with systemic lupus erythematosus and the antiphospholipid syndrome","volume":"20","author":"Hughson","year":"1992","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2019111903323609200_B31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MD.0b013e3182603598","article-title":"Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases","volume":"91","author":"Lechner","year":"2012","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"2019111903323609200_B32","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1200\/JOP.2016.012096","article-title":"Microangiopathic hemolytic anemia and thrombocytopenia in patients with cancer","volume":"12","author":"Morton","year":"2016","journal-title":"J Oncol Pract"},{"issue":"2","key":"2019111903323609200_B33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1258\/om.2011.100059","article-title":"Pregnancy-associated atypical haemolytic uraemic syndrome in the postpartum period: a case report and review of the literature","volume":"4","author":"Egbor","year":"2011","journal-title":"Obstet Med"},{"issue":"4","key":"2019111903323609200_B34","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2019111903323609200_B35","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ckj\/sft078","article-title":"Eculizumab and drug-induced haemolytic-uraemic syndrome","volume":"6","author":"Faguer","year":"2013","journal-title":"Clin Kidney J"},{"issue":"4","key":"2019111903323609200_B36","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.kint.2016.07.002","article-title":"Complement contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome","volume":"90","author":"Karpman","year":"2016","journal-title":"Kidney Int"},{"issue":"10","key":"2019111903323609200_B37","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00467-013-2561-1","article-title":"Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome","volume":"29","author":"Keir","year":"2014","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"2019111903323609200_B38","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.kint.2016.05.011","article-title":"Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury","volume":"90","author":"Ozaki","year":"2016","journal-title":"Kidney Int"},{"issue":"10","key":"2019111903323609200_B39","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1182\/blood.V97.10.3100","article-title":"Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome","volume":"97","author":"Karpman","year":"2001","journal-title":"Blood"},{"issue":"20","key":"2019111903323609200_B40","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1182\/blood-2010-09-309161","article-title":"Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome","volume":"117","author":"St\u00e5hl","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2019111903323609200_B41","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1182\/blood-2007-08-106153","article-title":"Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation","volume":"111","author":"St\u00e5hl","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2019111903323609200_B42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4049\/jimmunol.102.1.93","article-title":"A neutrophil chemotactic factor from human\u02b9\u20195","volume":"102","author":"Ward","year":"1969","journal-title":"J Immunol"},{"issue":"8","key":"2019111903323609200_B43","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.4049\/jimmunol.136.8.2999","article-title":"C5b-9 assembly: average binding of one C9 molecule to C5b-8 without poly-C9 formation generates a stable transmembrane pore","volume":"136","author":"Bhakdi","year":"1986","journal-title":"J Immunol"},{"issue":"1","key":"2019111903323609200_B44","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1084\/jem.156.1.268","article-title":"Molecular organization of C9 within the membrane attack complex of complement. Induction of circular C9 polymerization by the C5b-8 assembly","volume":"156","author":"Podack","year":"1982","journal-title":"J Exp Med"},{"issue":"5247","key":"2019111903323609200_B45","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1126\/science.271.5247.348","article-title":"C3d of complement as a molecular adjuvant: bridging innate and acquired immunity","volume":"271","author":"Dempsey","year":"1996","journal-title":"Science"},{"key":"2019111903323609200_B46","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1749-6632.1983.tb18116.x","article-title":"Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3","volume":"421","author":"Pangburn","year":"1983","journal-title":"Ann N Y Acad Sci"},{"issue":"12","key":"2019111903323609200_B47","doi-asserted-by":"crossref","first-page":"7194","DOI":"10.1073\/pnas.77.12.7194","article-title":"Covalent binding and hemolytic activity of complement proteins","volume":"77","author":"Law","year":"1980","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2019111903323609200_B48","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1182\/blood-2007-04-083170","article-title":"Factor H mediated cell surface protection from complement is critical for the survival of PNH erythrocytes","volume":"110","author":"Ferreira","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2019111903323609200_B49","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1084\/jem.154.3.856","article-title":"Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3","volume":"154","author":"Pangburn","year":"1981","journal-title":"J Exp Med"},{"issue":"10","key":"2019111903323609200_B50","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nri2620","article-title":"Complement regulators and inhibitory proteins","volume":"9","author":"Zipfel","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2019111903323609200_B51","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/labinvest.2010.173","article-title":"Dynamic control of the complement system by modulated expression of regulatory proteins","volume":"91","author":"Thurman","year":"2011","journal-title":"Lab Invest"},{"issue":"3","key":"2019111903323609200_B52","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1073\/pnas.82.3.859","article-title":"Identification of an additional class of C3-binding membrane proteins of human peripheral blood leukocytes and cell lines","volume":"82","author":"Cole","year":"1985","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2019111903323609200_B53","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1172\/JCI112773","article-title":"Interactions of the platelets in paroxysmal nocturnal hemoglobinuria with complement. Relationship to defects in the regulation of complement and to platelet survival in vivo","volume":"79","author":"Devine","year":"1987","journal-title":"J Clin Invest"},{"issue":"2-3","key":"2019111903323609200_B54","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.clim.2005.10.014","article-title":"Membrane complement regulatory proteins","volume":"118","author":"Kim","year":"2006","journal-title":"Clin Immunol"},{"issue":"11","key":"2019111903323609200_B55","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.4049\/jimmunol.0804031","article-title":"The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome","volume":"182","author":"Ferreira","year":"2009","journal-title":"J Immunol"},{"issue":"23","key":"2019111903323609200_B56","doi-asserted-by":"crossref","first-page":"15650","DOI":"10.1074\/jbc.M900814200","article-title":"Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome","volume":"284","author":"Lehtinen","year":"2009","journal-title":"J Biol Chem"},{"issue":"5","key":"2019111903323609200_B57","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1084\/jem.144.5.1147","article-title":"Modulation of the alternative complement pathways by beta 1 H globulin","volume":"144","author":"Whaley","year":"1976","journal-title":"J Exp Med"},{"issue":"1","key":"2019111903323609200_B58","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1006\/bbrc.1994.1008","article-title":"Regulation of alternative pathway complement activation by glycosaminoglycans: specificity of the polyanion binding site on factor H","volume":"198","author":"Meri","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"issue":"22","key":"2019111903323609200_B59","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1182\/blood-2015-11-680009","article-title":"Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome","volume":"127","author":"Hyv\u00e4rinen","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2019111903323609200_B60","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1172\/JCI16651","article-title":"Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome","volume":"111","author":"Manuelian","year":"2003","journal-title":"J Clin Invest"},{"issue":"7","key":"2019111903323609200_B61","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1681\/ASN.2005010103","article-title":"Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome","volume":"16","author":"Kavanagh","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2019111903323609200_B62","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40246-015-0029-z","article-title":"Complement regulator CD46: genetic variants and disease associations","volume":"9","author":"Liszewski","year":"2015","journal-title":"Hum Genomics"},{"issue":"5","key":"2019111903323609200_B63","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00467-009-1415-3","article-title":"A novel mutation in the complement factor B gene (CFB) and atypical hemolytic uremic syndrome","volume":"25","author":"Tawadrous","year":"2010","journal-title":"Pediatr Nephrol"},{"issue":"13","key":"2019111903323609200_B64","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2009-01-197640","article-title":"Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome","volume":"114","author":"Roumenina","year":"2009","journal-title":"Blood"},{"issue":"10","key":"2019111903323609200_B65","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2019111903323609200_B66","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2019111903323609200_B67","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype","volume":"24","author":"Bresin","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2019111903323609200_B68","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/ki.2013.373","article-title":"Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children","volume":"85","author":"Sinha","year":"2014","journal-title":"Kidney Int"},{"issue":"2","key":"2019111903323609200_B69","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1681\/ASN.2004050380","article-title":"Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome","volume":"16","author":"Dragon-Durey","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"2019111903323609200_B70","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.4049\/jimmunol.147.8.2638","article-title":"Membrane vesiculation protects erythrocytes from destruction by complement","volume":"147","author":"Iida","year":"1991","journal-title":"J Immunol"},{"issue":"1","key":"2019111903323609200_B71","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/(SICI)1096-8652(199609)53:1<22::AID-AJH5>3.0.CO;2-7","article-title":"Mechanism of intravascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH)","volume":"53","author":"Nakakuma","year":"1996","journal-title":"Am J Hematol"},{"issue":"3","key":"2019111903323609200_B72","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1046\/j.1523-1755.2001.060003831.x","article-title":"Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura","volume":"60","author":"Ruggenenti","year":"2001","journal-title":"Kidney Int"},{"issue":"10 Suppl 17","key":"2019111903323609200_B73","first-page":"1","article-title":"Atypical hemolytic uremic syndrome (aHUS): making the diagnosis","volume":"10","author":"Laurence","year":"2012","journal-title":"Clin Adv Hematol Oncol"},{"key":"2019111903323609200_B74","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev.ph.49.030187.001141","article-title":"Red cell deformability and its relevance to blood flow","volume":"49","author":"Chien","year":"1987","journal-title":"Annu Rev Physiol"},{"issue":"2","key":"2019111903323609200_B75","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/ijlh.12156","article-title":"Paroxysmal nocturnal haemoglobinuria. Experience over a 10 years period","volume":"36","author":"Canalejo","year":"2014","journal-title":"Int J Lab Hematol"},{"issue":"4","key":"2019111903323609200_B76","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1172\/JCI36088","article-title":"C3b deposition on human erythrocytes induces the formation of a membrane skeleton-linked protein complex","volume":"119","author":"Karnchanaphanurach","year":"2009","journal-title":"J Clin Invest"},{"issue":"3","key":"2019111903323609200_B77","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2141.1985.tb02849.x","article-title":"Effect of complement on the viscoelastic properties of human erythrocyte membrane","volume":"61","author":"Sung","year":"1985","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111903323609200_B78","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00281-005-0004-1","article-title":"Emission of membrane vesicles: roles in complement resistance, immunity and cancer","volume":"27","author":"Pilzer","year":"2005","journal-title":"Springer Semin Immunopathol"},{"issue":"24","key":"2019111903323609200_B79","doi-asserted-by":"crossref","first-page":"19904","DOI":"10.1074\/jbc.M111.333039","article-title":"Caveolin-1 and dynamin-2 are essential for removal of the complement C5b-9 complex via endocytosis","volume":"287","author":"Moskovich","year":"2012","journal-title":"J Biol Chem"},{"issue":"4","key":"2019111903323609200_B80","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1055\/s-0034-1375701","article-title":"Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS)","volume":"40","author":"Sethi","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"2019111903323609200_B81","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1567-5769(00)00047-3","article-title":"Complement factor H and hemolytic uremic syndrome","volume":"1","author":"Zipfel","year":"2001","journal-title":"Int Immunopharmacol"},{"key":"2019111903323609200_B82","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-3-319-18603-0_3","article-title":"Role of complement on broken surfaces after trauma","volume":"865","author":"Huber-Lang","year":"2015","journal-title":"Adv Exp Med Biol"},{"key":"2019111903323609200_B83","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-1-4419-0901-5_8","article-title":"Target pattern recognition by complement proteins of the classical and alternative pathways","volume":"653","author":"Kang","year":"2009","journal-title":"Adv Exp Med Biol"},{"issue":"11","key":"2019111903323609200_B84","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.imbio.2012.07.024","article-title":"The complement system in ischemia-reperfusion injuries","volume":"217","author":"Gorsuch","year":"2012","journal-title":"Immunobiology"},{"key":"2019111903323609200_B85","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1196\/annals.1352.032","article-title":"Hemolytic uremic syndrome: an example of insufficient complement regulation on self-tissue","volume":"1056","author":"Atkinson","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"2019111903323609200_B86","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0002-9440(10)61205-9","article-title":"Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site","volume":"167","author":"Jokiranta","year":"2005","journal-title":"Am J Pathol"},{"issue":"6","key":"2019111903323609200_B87","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1084\/jem.20041497","article-title":"Platelet activation leads to activation and propagation of the complement system","volume":"201","author":"Del Conde","year":"2005","journal-title":"J Exp Med"},{"issue":"2","key":"2019111903323609200_B88","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2013-03-489245","article-title":"Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome","volume":"122","author":"Frimat","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019111903323609200_B89","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1055\/s-0032-1333538","article-title":"Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia","volume":"39","author":"George","year":"2013","journal-title":"Semin Thromb Hemost"},{"issue":"17","key":"2019111903323609200_B90","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111903323609200_B91","doi-asserted-by":"crossref","first-page":"834","DOI":"10.5858\/2003-127-834-TTPAHU","article-title":"Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases","volume":"127","author":"Hosler","year":"2003","journal-title":"Arch Pathol Lab Med"},{"issue":"3 Suppl 1","key":"2019111903323609200_B92","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/SHK.0000000000000675","article-title":"Complement activation in trauma patients alters platelet function","volume":"46","author":"Atefi","year":"2016","journal-title":"Shock"},{"issue":"4","key":"2019111903323609200_B93","doi-asserted-by":"crossref","first-page":"e18812","DOI":"10.1371\/journal.pone.0018812","article-title":"Requirements for membrane attack complex formation and anaphylatoxins binding to collagen-activated platelets","volume":"6","author":"Martel","year":"2011","journal-title":"PLoS One"},{"issue":"20","key":"2019111903323609200_B94","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1182\/blood-2009-03-205096","article-title":"Platelet-associated complement factor H in healthy persons and patients with atypical HUS","volume":"114","author":"Licht","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2019111903323609200_B95","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1182\/blood.V76.2.361.361","article-title":"Consecutive enzyme cascades: complement activation at the cell surface triggers increased tissue factor activity","volume":"76","author":"Carson","year":"1990","journal-title":"Blood"},{"issue":"2","key":"2019111903323609200_B96","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1055\/s-0038-1655974","article-title":"C5a induces tissue factor activity on endothelial cells","volume":"77","author":"Ikeda","year":"1997","journal-title":"Thromb Haemost"},{"issue":"9","key":"2019111903323609200_B97","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1084\/jem.185.9.1619","article-title":"The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity","volume":"185","author":"Tedesco","year":"1997","journal-title":"J Exp Med"},{"issue":"1","key":"2019111903323609200_B98","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00281-011-0280-x","article-title":"Interactions between coagulation and complement--their role in inflammation","volume":"34","author":"Oikonomopoulou","year":"2012","journal-title":"Semin Immunopathol"},{"issue":"Suppl 1","key":"2019111903323609200_B99","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1111\/jth.12950","article-title":"Reincarnation of ancient links between coagulation and complement","volume":"13","author":"Conway","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2019111903323609200_B100","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1084\/jem.157.6.2029","article-title":"Expression of C5a-like biological activities by the fifth component of human complement (C5) upon limited digestion with noncomplement enzymes without release of polypeptide fragments","volume":"157","author":"Wetsel","year":"1983","journal-title":"J Exp Med"},{"issue":"8","key":"2019111903323609200_B101","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1182\/blood-2012-02-412080","article-title":"Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway","volume":"120","author":"Krisinger","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111903323609200_B102","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1172\/JCI118195","article-title":"Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation","volume":"96","author":"Rinder","year":"1995","journal-title":"J Clin Invest"},{"issue":"4","key":"2019111903323609200_B103","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood.V68.4.875.875","article-title":"Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase","volume":"68","author":"Wiedmer","year":"1986","journal-title":"Blood"},{"issue":"2","key":"2019111903323609200_B104","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood.V68.2.556.556","article-title":"Repolarization of the membrane potential of blood platelets after complement damage: evidence for a Ca++-dependent exocytotic elimination of C5b-9 pores","volume":"68","author":"Sims","year":"1986","journal-title":"Blood"},{"issue":"9","key":"2019111903323609200_B105","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol"},{"issue":"15","key":"2019111903323609200_B106","doi-asserted-by":"crossref","first-page":"9500","DOI":"10.1074\/jbc.M114.630871","article-title":"The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease","volume":"290","author":"Bhattacharjee","year":"2015","journal-title":"J Biol Chem"},{"key":"2019111903323609200_B107","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4049\/jimmunol.94.2.307","article-title":"Beta-1-C-globulin: An \u201cacute phase\u201d serum reactant of human serum","volume":"94","author":"Hornung","year":"1965","journal-title":"J Immunol"},{"issue":"2","key":"2019111903323609200_B108","first-page":"251","article-title":"C3 proactivator (C3PA) as an acute phase reactant","volume":"18","author":"Schutte","year":"1974","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"2019111903323609200_B109","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/0002-9343(56)90127-9","article-title":"Serologic tests for inflammation; serum complement, c-reactive protein and erythrocyte sedimentation rate in myocardial infarction","volume":"20","author":"Boltax","year":"1956","journal-title":"Am J Med"},{"issue":"16","key":"2019111903323609200_B110","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1128\/jb.178.16.4854-4860.1996","article-title":"Cloning and characterization of nanB, a second Streptococcus pneumoniae neuraminidase gene, and purification of the NanB enzyme from recombinant Escherichia coli","volume":"178","author":"Berry","year":"1996","journal-title":"J Bacteriol"},{"issue":"4606","key":"2019111903323609200_B111","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/181377a0","article-title":"The influenza virus neuraminidase","volume":"181","author":"Gottschalk","year":"1958","journal-title":"Nature"},{"issue":"3","key":"2019111903323609200_B112","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.mehy.2013.05.030","article-title":"Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to Streptococcus pneumoniae?","volume":"81","author":"Gilbert","year":"2013","journal-title":"Med Hypotheses"},{"issue":"2","key":"2019111903323609200_B113","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/cei.12890","article-title":"Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders","volume":"187","author":"Wehling","year":"2016","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"2019111903323609200_B114","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.ajkd.2015.04.010","article-title":"Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update","volume":"66","author":"Ardissino","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2019111903323609200_B115","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation","volume":"12","author":"Fakhouri","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"21","key":"2019111903323609200_B116","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","article-title":"Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS","volume":"125","author":"Cofiell","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2019111903323609200_B117","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int"},{"issue":"6","key":"2019111903323609200_B118","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ckj\/sfv101","article-title":"Eculizumab for rescue of thrombotic microangiopathy in PM-Scl antibody-positive autoimmune overlap syndrome","volume":"8","author":"Thomas","year":"2015","journal-title":"Clin Kidney J"},{"issue":"1","key":"2019111903323609200_B119","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/j.ajkd.2014.07.031","article-title":"Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab","volume":"65","author":"El-Husseini","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2019111903323609200_B120","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00467-014-2944-y","article-title":"Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy","volume":"30","author":"Coppo","year":"2015","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"2019111903323609200_B121","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/rheumatology\/kev371","article-title":"A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor","volume":"55","author":"Wig","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"26","key":"2019111903323609200_B122","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1097\/MD.0000000000000143","article-title":"Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report","volume":"93","author":"Kronbichler","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"2019111903323609200_B123","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/1752-1947-8-307","article-title":"Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report","volume":"8","author":"Kourouklaris","year":"2014","journal-title":"J Med Case Reports"},{"issue":"4","key":"2019111903323609200_B124","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/ckj\/sfw035","article-title":"Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab","volume":"9","author":"Jin","year":"2016","journal-title":"Clin Kidney J"},{"issue":"5","key":"2019111903323609200_B125","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.nefro.2015.07.005","article-title":"An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document","volume":"35","author":"Campistol","year":"2015","journal-title":"Nefrologia"},{"issue":"2","key":"2019111903323609200_B126","doi-asserted-by":"crossref","first-page":"11","DOI":"10.21767\/2472-5056.100011","article-title":"Typical Hus: Evidence of acute phase complement activation from a daycare outbreak","volume":"1","author":"Brady","year":"2016","journal-title":"J Clin Exp Nephrol"},{"issue":"24","key":"2019111903323609200_B127","doi-asserted-by":"crossref","first-page":"e1000","DOI":"10.1097\/MD.0000000000001000","article-title":"Eculizumab in Typical hemolytic uremic syndrome (HUS) with neurological involvement","volume":"94","author":"Pape","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"2019111903323609200_B128","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/bjh.12387","article-title":"Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up","volume":"162","author":"Tsai","year":"2013","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111903323609200_B129","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/bjh.12718","article-title":"How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome","volume":"164","author":"Scully","year":"2014","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111903323609200_B130","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1053\/j.ajkd.2015.06.032","article-title":"Treatment of congenital thrombotic thrombocytopenic purpura with eculizumab","volume":"66","author":"Pecoraro","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2019111903323609200_B131","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1365-2141.2012.09084.x","article-title":"Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura","volume":"157","author":"Chapin","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111903323609200_B132","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2014-06-579953","article-title":"Loss of DGK\u03b5 induces endothelial cell activation and death independently of complement activation","volume":"125","author":"Bruneau","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111903323609200_B133","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.ajkd.2013.08.031","article-title":"Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency","volume":"63","author":"Cornec-Le Gall","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"25","key":"2019111903323609200_B134","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1182\/blood-2012-09-311381","article-title":"Thrombosis in paroxysmal nocturnal hemoglobinuria","volume":"121","author":"Hill","year":"2013","journal-title":"Blood"},{"issue":"Suppl 1","key":"2019111903323609200_B135","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.thromres.2014.03.014","article-title":"Crosstalk between the coagulation and complement systems in sepsis","volume":"133","author":"Lupu","year":"2014","journal-title":"Thromb Res"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/21\/2847\/1401185\/blood709865.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/21\/2847\/1401185\/blood709865.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T04:35:18Z","timestamp":1692765318000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/21\/2847\/36275\/HUS-and-atypical-HUS"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,25]]},"references-count":135,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2017,5,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-11-709865","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,25]]}}}